2019 AACI CAR T Symposium

When:  Oct 21, 2019 from 14:00 to 17:00 (ET)
Presented by the Association of American Cancer Institutes, in collaboration with the Society for Immunotherapy of Cancer

The Present Landscape and Future Considerations

Program Description
More than half of AACI’s member centers have been approved to provide tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (YESCARTA®) CAR T-cell therapies for the treatment of certain relapsed or refractory leukemias and lymphomas. However, only a small fraction of 8,500 eligible patients received CAR T treatment in 2018. The 2019 AACI CAR T Symposium aims to identify the key challenges to patient access and delivery of CAR T, and to discuss potential solutions to address barriers to care. The meeting will bring together academic and community clinical physicians, clinical administrators, researchers, clinical directors for cellular and transplantation programs, nursing managers, clinical research directors, patient advocates, government employees, and industry stakeholders. As part of the program’s learning objectives, attendees will discuss:
  • Financial and technical challenges of manufacturing and administering CAR T therapy at academiccancer centers and innovative solutions to address barriers to care
  • Barriers associated with navigating the health care system and steps cancer centers can take toprovide quality care while minimizing complications for patients
  • Challenges and opportunities for collaboration between academia, government, industry, and theprivate sector to leverage the benefits of CAR T therapy by improving the safety and efficacy forpatients while reducing manufacturing costs that will ultimately reduce cost of care
  • Opportunities for advancing cellular therapy clinical research at academic cancer centers


2:00 – 2:10 p.m.

Joseph McGuirk, DO – The University of Kansas Cancer Center

2:10 – 2:30 p.m.

Keynote: The Present Landscape and Future Considerations of CAR T

2:30 – 3:30 p.m.

Navigating the Health System to Establish and Administer a CAR T Program

Moderator: Clint L. Divine, MBA, MSM – The University of Kansas Cancer Center

Matthew A. Lunning, DO – Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center

Robert Richards, MBA – Abramson Cancer Center of the University of Pennsylvania

3:30 – 3:45 p.m.


3:45 – 4:45 p.m.

Exploring the Value and Cost-Effectiveness of CAR T Cell Therapy

Moderator: Matthew H. Carabasi, MD – Sidney Kimmel Cancer Center at Jefferson Health

Rena M. Conti, PhD – Boston University

Krishna Komanduri, MD – Sylvester Comprehensive Cancer Center, University of Miami Health System

Mark Trusheim, MSc – Massachusetts Institute of Technology

4:45 – 5:00 p.m.

Closing Remarks
Joseph McGuirk, DO – The University of Kansas Cancer Center

For more information or to register, please click here.


The Mayflower Hotel
1127 Connecticut Avenue NW
Washington, DC 20036